Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Takeshi Suzuki, Gregory A. Kopia, Shin-ichiro Hayashi et al. · Circulation · 2001
BACKGROUND: The purpose of this study was to determine the efficacy of stent-based delivery of sirolimus (SRL) alone or in combination with dexamethasone (DEX) to reduce in-stent neointimal hyperplasia. SRL is a potent immunosuppressive agent that inhibits SMC proliferation by blocking cell cycle progression. METHODS AND RESULTS: Stents were coated with a nonerodable polymer containing 185 microgram SRL, 350 microgram DEX, or 185 microgram SRL and 350 microgram DEX. Polymer biocompatibility studies in the porcine and canine models showed acceptable tissue response at 60 days. Forty-seven stents (metal, n=13; SRL, n=13; DEX, n=13; SRL and DEX, n=8) were implanted in the coronary arteries of 16 pigs. The tissue level of SRL was 97+/-13 ng/artery, with a stent content of 71+/-10 microgram at 3 days. At 7 days, proliferating cell nuclear antigen and retinoblastoma protein expression were reduced 60% and 50%, respectively, by the SRL stents. After 28 days, the mean neointimal area was 2.47+/-1.04 mm(2) for the SRL alone and 2.42+/-1.04 mm(2) for the combination of SRL and DEX compared with the metal (5.06+/-1.88 mm(2), P<0.0001) or DEX-coated stents (4.31+/-3.21 mm(2), P<0.001), resulting in a 50% reduction of percent in-stent stenosis. CONCLUSIONS: Stent-based delivery of SRL via a nonerodable polymer matrix is feasible and effectively reduces in-stent neointimal hyperplasia by inhibiting cellular proliferation.
Cited by 708 works. doi:10.1161/hc3601.093987 Open-access PDF
Authors
- Takeshi Suzuki
- Gregory A. Kopia
- Lynn R. Bailey
- Gerard R. Llanos
- Robert L. Wilensky
- Bruce D. Klugherz
- Pallassana Narayan
- Martin B. Leon
- Alan C. Yeung
- Fermin O. Tio
- Philip S. Tsao
- Robert Falotico
- Andrew J. Carter
References
- Angiographic Patterns of In-Stent Restenosis
- Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries
- Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle
- Pathology of Acute and Chronic Coronary Stenting in Humans
- Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells
- In-Stent Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal Hyperplasia
- Rapamycin inhibits vascular smooth muscle cell migration.
- Frontiers in Interventional Cardiology
- Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen
- Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986